New combo therapy aims to tame prostate cancer with fewer side effects

NCT ID NCT06111781

First seen Jan 07, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This study tests whether adding a short course of the oral hormone drug Relugolix to precise radiation (SBRT) works better than radiation alone for men with a certain type of prostate cancer. About 60 men will be randomly assigned to one of the two treatments. The goal is to see if the combination leads to lower PSA levels and better preserves sexual and hormonal function compared to standard longer hormone therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10017, United States

    Contact

    Contact Email: •••••@•••••

  • University of Washington

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Yale Cancer Center

    RECRUITING

    New Haven, Connecticut, 06520, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.